What it is
SS-31 is a man-made peptide, which is a short chain of amino acids (the building blocks of proteins). It has just four amino acids, so chemists call it a tetrapeptide. Its official drug name is elamipretide. Older names in the research papers and trial records are MTP-131 and Bendavia. It was developed as a medicine by the US company Stealth BioTherapeutics.
More on what it is and where it came from
On 19 September 2025 the US Food and Drug Administration (FDA) approved elamipretide, under the brand name Forzinity, to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. Barth syndrome is a rare inherited disease that affects mitochondria, the parts of a cell that turn food into usable energy. The FDA described it as rare, serious and life-threatening. The approval came through the FDA's accelerated pathway. That means it rests on an early sign of benefit (stronger knee muscles) and the company must run a further trial to confirm that patients really benefit.
That approval covers one prescription product for one rare disease. It does not cover the vials sold online as 'SS-31' for 'research'. Those are unapproved, and the FDA wrote to several sellers about them in August 2026. Elamipretide has also been tested in mitochondrial muscle disease, heart failure, heart attack and an eye disease called dry age-related macular degeneration. In each of those, the main placebo-controlled trial did not meet its main goals.
SS-31 belongs to a family called the Szeto-Schiller (SS) peptides, named after the researchers H. H. Szeto and P. W. Schiller. In 2004 they and their colleagues published a paper describing small peptides that pass into cells and collect at the inner membrane of mitochondria. At first the peptides were described as antioxidants, meaning substances that mop up reactive, damaging forms of oxygen. In 2013 Szeto's group reported that SS-31 attaches to cardiolipin, a fat found in that membrane. Stealth BioTherapeutics took the peptide into human trials under the names Bendavia and MTP-131; a heart attack trial began in April 2012, according to the ClinicalTrials.gov registry. The company applied to the FDA for approval in Barth syndrome on 29 January 2024, and approval followed on 19 September 2025.
How it is thought to work
Mitochondria have a folded inner membrane where most of a cell's energy is made. Cardiolipin is a fat molecule found in that inner membrane, and the folds need it to keep their shape. In a 2013 study, researchers reported that SS-31 attached tightly to cardiolipin in laboratory tests. In rats whose kidneys had their blood supply cut off and restored, animals given SS-31 beforehand had better-preserved membrane folds and their kidney cells recovered their energy supply faster.
More on how it works
The FDA label describes elamipretide as 'a mitochondrial cardiolipin binder that localizes to the inner mitochondrial membrane'. Barth syndrome is a genetic disorder of how the body makes cardiolipin, which is why the drug was tested there.
How much of this happens in people is less clear. A long-term follow-up of Barth syndrome patients reported that a blood marker of abnormal cardiolipin improved over time. But when the FDA reviewed the data in May 2025 it said no treatment effect on that marker had been shown, because some of the largest falls happened while patients were on placebo. So the idea is well supported in cells and animals, and only partly tested in humans.
What is established in people
Elamipretide has been tested in people in several conditions, always in patients except for one single-dose study in healthy older adults. Its one approval, for Barth syndrome, rests on knee-strength gains seen in 8 to 10 patients during a follow-on phase with no comparison group; the 12-person placebo-controlled part of that trial showed no benefit, which is why the FDA used its accelerated pathway and required a confirmatory trial. The larger placebo-controlled trials (218 people with mitochondrial muscle disease, 176 with dry macular degeneration, 71 with heart failure, and a heart attack trial of 300) did not meet their main goals. Nothing has been established about anti-ageing, athletic performance or general 'mitochondrial health' in healthy people.
What the studies found
12 studies, human trials first. Each links to the paper or registry record.
- Human trial2026
ReNEW: Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
No results yet.
Full finding, who was studied, and limits
Who: 313 people aged 55 or older with dry age-related macular degeneration, randomised 2 to 1 to elamipretide or placebo for 96 weeks. Double-masked.
No results yet. The trial started on 30 May 2024 and is listed as active but no longer recruiting. Its main measure is the rate of loss of light-sensing cells on eye scans at 48 weeks, the same scan measure that looked favourable in the phase 2 trial. The registry gives August 2027 as the estimated primary completion date (when the last participant is measured for the main goal) and September 2027 for study completion.
Read with care: An ongoing trial proves nothing yet. The ReCLAIM-2 paper names a second phase 3 trial, ReGAIN; we could not find a registry record for it.
- Human trial2024
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER
The paper reported that walking distance was 96.1 metres higher at week 168 than at the start of the extension, that fatigue scores stayed below their starting level, and that injection-site reactions were the most common side effect.
Full finding, who was studied, and limits
Who: The 10 TAZPOWER participants who continued into the open-label extension; 8 reached the 168-week visit. No comparison group.
The paper reported that walking distance was 96.1 metres higher at week 168 than at the start of the extension, that fatigue scores stayed below their starting level, and that injection-site reactions were the most common side effect. The FDA based its approval on knee muscle strength instead. According to the label, the middle (median) knee strength at the start was 124 newtons. In the placebo-controlled part the median change at 12 weeks was 4 newtons on the drug and -5 on placebo. In the extension the median change from the start was 34 newtons at week 12 (10 people), 68 at week 24 (9 people) and 63 at week 168 (8 people).
Read with care: Eight to ten people, with no control group, and everyone knew they were on the drug. In its May 2025 letter refusing approval, the FDA said it could not conclude there was a meaningful effect from this phase, because the tests depend on effort and patients knew they were treated, and because improvements had also been seen on placebo in Part 1. Whether stronger knee muscles lead to real-life benefit is what the required confirmatory trial is meant to show.
- Human trial2024
ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation
Neither main goal was met.
Full finding, who was studied, and limits
Who: 176 people aged 55 or older with dry age-related macular degeneration and patches of retinal cell loss away from the centre of vision. Randomised, double-masked, 117 to elamipretide and 59 to placebo, for 48 weeks.
Neither main goal was met. The change in low-light vision was -3.0 letters on the drug and -4.4 on placebo (p = 0.49). Growth of the damaged area, measured on a square-root scale (the square root of the area, in millimetres), was 0.312 mm on the drug and 0.275 mm on placebo (p = 0.34). In secondary measures, loss of a layer of light-sensing cells seen on eye scans progressed 43% less on the drug, and 14.6% of people on the drug gained two or more lines of low-light vision compared with 2.1% on placebo.
Read with care: The positive results were secondary or exploratory measures, were not adjusted for the number of comparisons made, and the scan result is a stand-in for vision, not vision itself. More people left the trial early on the drug (29%) than on placebo (14%). Two authors work for Stealth BioTherapeutics.
- Human trial2023
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial
This is the largest completed trial of elamipretide with published results, and it did not meet either main goal.
Full finding, who was studied, and limits
Who: 218 adults with genetically confirmed primary mitochondrial myopathy, a group of inherited muscle diseases caused by faulty mitochondria. Mean age 45.6; 64% women. Randomised, double-blind, 109 to elamipretide and 109 to placebo, for 24 weeks. Phase 3.
This is the largest completed trial of elamipretide with published results, and it did not meet either main goal. The difference in six-minute walk distance between drug and placebo was -3.2 metres (95% confidence interval -18.7 to 12.3; p = 0.69). The difference in the fatigue score was -0.07 points (p = 0.37). The journal classed this as high-quality evidence that elamipretide does not improve walking distance or fatigue at 24 weeks in this disease. The registry records that the trial was terminated because the double-blind part did not meet its primary endpoints.
Read with care: A later look at sub-groups suggested people with one type of genetic fault (in nuclear DNA) might respond. That kind of after-the-fact finding can arise by chance. A follow-up phase 3 trial in 102 such patients (NuPower, NCT05162768) finished in 2024, and no results were posted on the registry when we checked. Funded by Stealth BioTherapeutics.
Neurology 2023;101(3):e238-e252 (ClinicalTrials.gov NCT03323749) · pubmed.ncbi.nlm.nih.gov
- Human trial2022
Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome
Treated patients walked further in six minutes than the matched untreated patients: 79.7 metres further at week 64 and 91.0 metres further at week 76.
Full finding, who was studied, and limits
Who: 8 patients from the TAZPOWER extension, compared after the fact with 19 untreated Barth syndrome patients from existing records. Not a randomised trial.
Treated patients walked further in six minutes than the matched untreated patients: 79.7 metres further at week 64 and 91.0 metres further at week 76. Muscle strength was 40.8 and 56.7 newtons higher at the same time points.
Read with care: A look-back comparison of 8 treated people against patients from records, not a trial. The FDA's May 2025 letter listed problems with it: possible bias in how patients were selected, limits of the statistical matching, comparison data that were all estimated between visits, and a missing audit trail for the comparison group. At the FDA advisory committee meeting in October 2024, members also raised concerns about the matching method. The authors include company employees.
Orphanet Journal of Rare Diseases 2022;17(1):336 (also called SPIBA-001) · pubmed.ncbi.nlm.nih.gov
- Human trial2021
A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism
In the placebo-controlled part, elamipretide was no better than placebo.
Full finding, who was studied, and limits
Who: 12 males aged 12 to 35 with genetically confirmed Barth syndrome, at one US hospital. Part 1 was a randomised, double-blind crossover: each person had 12 weeks of elamipretide and 12 weeks of placebo, in random order, with a 4-week break between. Part 2 was open-label, meaning everyone knew they were getting the drug: 10 people continued and 8 reached 36 weeks.
In the placebo-controlled part, elamipretide was no better than placebo. The difference in six-minute walk distance was -0.8 metres (p = 0.97), the difference in the fatigue score was 0.06 points (p = 0.89), and the difference in knee muscle strength was 6.7 newtons (p = 0.65). In the open-label part, at 36 weeks, walking distance had risen by 95.9 metres, the fatigue score had improved by 2.1 points, and knee strength had risen by 56.0 newtons, all compared with the start of that part. Skin reactions at the injection site affected all 12 people on the drug; two of the ten people in the open-label part stopped because of them.
Read with care: Twelve people at one site. The only part with a placebo comparison showed no benefit. The improvements came in the part where patients and staff knew who was on the drug, and walking and strength tests depend on effort. The trial was paid for by Stealth BioTherapeutics, which helped design it and analyse the data.
- Human trial2021
In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial
Straight after the infusion, the hand muscle's maximum energy-making capacity had risen by 27% in the drug group and 12% in the placebo group (p = 0.055 for the raw change; p = 0.045 for the percentage change).
Full finding, who was studied, and limits
Who: 39 healthy adults aged 60 to 85 (46% women) chosen because their muscle mitochondria worked poorly. Randomised, double-blind: 19 received a single infusion of elamipretide into a vein and 20 received placebo.
Straight after the infusion, the hand muscle's maximum energy-making capacity had risen by 27% in the drug group and 12% in the placebo group (p = 0.055 for the raw change; p = 0.045 for the percentage change). Seven days later there was no difference. Resistance to muscle fatigue did not change, and neither did a measure of how efficiently resting mitochondria worked.
Read with care: This is the only published placebo-controlled test in healthy older people. It used one dose, measured one small hand muscle with a scanner, and found an effect that was borderline and gone within a week. It did not measure strength, endurance, health or lifespan. The authors said better blood flow could explain the result. Funded partly by Stealth BioTherapeutics; three authors had been paid consultants to the company.
PLoS One 2021;16(7):e0253849 (ClinicalTrials.gov NCT02245620) · pubmed.ncbi.nlm.nih.gov
- Human trial2020
Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial
The main measure was the volume of blood left in the heart's main chamber after each beat, measured by MRI scan.
Full finding, who was studied, and limits
Who: 71 patients with heart failure in which the heart pumps weakly (ejection fraction 40% or less). Mean age 65; 24% women. Randomised, double-blind, to a lower dose, a higher dose or placebo for 28 days.
The main measure was the volume of blood left in the heart's main chamber after each beat, measured by MRI scan. Neither dose improved it compared with placebo (differences of -0.3 mL, p = 0.90, and 2.3 mL, p = 0.28). The share of blood pumped out with each beat (ejection fraction) did not improve either. The drug was well tolerated.
Read with care: Small and only four weeks long. Two other phase 2 heart failure trials are listed on ClinicalTrials.gov as completed in 2017 with no results posted: one in 46 people with a different type of heart failure (NCT02814097) and one in 308 people in hospital with heart failure (NCT02914665). We found no journal report of either.
- Human trial2016
EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention
The drug did not reduce the amount of heart muscle damage.
Full finding, who was studied, and limits
Who: Patients having a first major heart attack who were treated with an emergency procedure to reopen the blocked artery. The registry records 300 people randomised (152 to the drug, 148 to placebo); the main analysis used a pre-defined group of 117. The drug or placebo was given into a vein around the time of the procedure.
The drug did not reduce the amount of heart muscle damage. The main measure, a blood marker of heart damage tracked over 72 hours, was almost the same in both groups (5570 on the drug and 5785 on placebo, in the marker's units; not a significant difference). Heart scans and clinical outcomes showed no improvement either. The paper described the drug as safe and well tolerated.
Read with care: A single short infusion in an emergency setting, which says little about longer use. The registry's side-effect section lists more deaths in the drug group than the placebo group (see the safety section); the trial was not designed to test this and the published abstract does not discuss it.
- Animal study2019
Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice
In old mice, SS-31 reversed the age-related fall in the muscle's maximum energy production.
Full finding, who was studied, and limits
Who: Female mice: young (5 months old) and old (26 months old). The old mice were given SS-31 for 8 weeks. The abstract does not give the number of animals.
In old mice, SS-31 reversed the age-related fall in the muscle's maximum energy production. Treated old mice had a leg muscle that was heavier and tired less quickly, and they ran for longer on a treadmill than before treatment and than untreated old mice.
Read with care: Mice, not people. This kind of result is the main basis for anti-ageing claims made online. A related mouse study in 2025 found SS-31 did not reduce small brain bleeds in old mice with high blood pressure, so not every ageing-related test has been positive. One author, H. H. Szeto, is a co-inventor of the peptide family.
Free Radical Biology and Medicine 2019;134:268-281 · pubmed.ncbi.nlm.nih.gov
- Animal study2013
The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin
A fluorescent version of SS-31 attached tightly to cardiolipin in laboratory tests.
Full finding, who was studied, and limits
Who: Laboratory binding tests plus rats whose kidneys had their blood supply cut off and then restored. The abstract does not give the number of animals.
A fluorescent version of SS-31 attached tightly to cardiolipin in laboratory tests. Rats given SS-31 before the blood supply was cut had better-preserved folds in their mitochondrial membranes, less swelling of mitochondria, faster recovery of the cells' energy supply, and less kidney damage.
Read with care: Rats and test tubes. This is the main source for the cardiolipin explanation, and it comes from the group that invented the peptide. The animals were treated before the injury, which is not how most human illness is treated.
Journal of the American Society of Nephrology 2013;24(8):1250-1261 · pubmed.ncbi.nlm.nih.gov
- Cell study2004
Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury
This is the founding paper for the peptide family, with Szeto and Schiller among its authors.
Full finding, who was studied, and limits
Who: Nerve-like cells grown in the laboratory, mitochondria isolated from tissue, and animal hearts kept working outside the body. No people.
This is the founding paper for the peptide family, with Szeto and Schiller among its authors. The peptides passed into cells and built up about 1000-fold at the inner membrane of mitochondria. They lowered reactive oxygen in cells, reduced cell death caused by a toxic chemical, stopped isolated mitochondria from swelling, and improved the pumping force of hearts recovering from a loss of blood flow. Versions of the peptide without the modified tyrosine (called Dmt) did not work.
Read with care: Cells, isolated mitochondria and isolated hearts only. The abstract describes the peptide family and does not name SS-31 itself. The explanation given then was antioxidant action; the cardiolipin explanation came later.
Journal of Biological Chemistry 2004;279(33):34682-34690 · pubmed.ncbi.nlm.nih.gov
Safety findings
- Injection-site reactions were the main side effect. In the placebo-controlled Barth syndrome trial on the FDA label (12 people, each given both drug and placebo), redness at the injection site occurred in 12 of 12 on the drug and 3 of 12 on placebo; pain in 9 and 5; hardening of the skin in 8 and 2; itching in 8 and 2; bruising in 3 and 0; hives in 3 and 0. Source: dailymed.nlm.nih.gov
- Allergic reactions: the label warns that hypersensitivity reactions, including serious allergic reactions needing emergency treatment, have been reported. Reported reactions included rashes, raised skin bumps, eczema-like skin inflammation and cough, and the label says they may occur within minutes to months of starting. Source: dailymed.nlm.nih.gov
- Blood counts: the label says a type of white blood cell (eosinophils) often rose with 30 days or more of use, peaking at about day 90 and returning to the starting level within 6 to 12 months of continued use or after stopping, without symptoms. Source: dailymed.nlm.nih.gov
- Cancer risk has not been studied: the label states that carcinogenicity studies have not been conducted with elamipretide. As a condition of approval, the FDA required the company to complete two animal cancer studies (one in mice and a two-year study in rats, with the rat report due in January 2030) and a drug-interaction study with metformin. Source: accessdata.fda.gov
5 more safety findings
- The approved product contains benzyl alcohol as a preservative. The label says it is not approved for newborns and is not for use in a vein, because benzyl alcohol given into a vein has been linked to serious and fatal reactions in premature and low-birth-weight babies. Safety and effectiveness have not been established in children weighing less than 30 kg, and there are no data in human pregnancy. Source: dailymed.nlm.nih.gov
- In the 218-person mitochondrial myopathy trial (registry results, 24-week double-blind part), injection-site redness was recorded in 94 of 109 people on the drug (86%) and 31 of 109 on placebo (28%); itching in 82 (75%) and 10 (9%); swelling in 42 and 7; hives in 14 and 0. A raised eosinophil count was recorded in 7 on the drug and none on placebo. Serious adverse events (medical events classed as serious) occurred in 5 of 109 on the drug and 3 of 109 on placebo. There were no deaths. Source: clinicaltrials.gov
- In the 176-person dry macular degeneration trial, side effects of any kind were reported by 86% on the drug and 71% on placebo, and injection-site reactions by 60% and 27%. Serious adverse events occurred in 15% on the drug and 10% on placebo; none was judged to be caused by the drug. Two people on the drug died (one from COVID-19, one from respiratory failure); both deaths were judged unrelated. 29% of the drug group left the trial early compared with 14% of the placebo group. Source: pubmed.ncbi.nlm.nih.gov
- Heart attack trial (EMBRACE STEMI): the registry's side-effect section lists 10 deaths among 150 people given the drug (6.7%) and 3 among 147 given placebo (2.0%), and serious adverse events in 20 (13.3%) and 14 (9.5%). The same record's participant-flow section lists death as the reason for leaving the study for 3 people on the drug and 1 on placebo, so the two sections do not match. The published paper called the drug safe and well tolerated. These were very ill patients given one short infusion, the numbers are small, and the registry does not say the drug caused any death. This should be read as an unexplained difference, not as proof of harm. Source: clinicaltrials.gov
- Unapproved products: in warning letters dated 24 August 2026 to companies selling SS-31 and other peptides labelled 'for research use only', the FDA said these were unapproved new drugs intended for human use. It also said injectable products can cause serious harm because they are delivered directly into the body and bypass some of its defences against toxins and germs. No study has checked what the products sold online as SS-31 actually contain. Source: fda.gov
Rules and status
Approved in the United States for one use only. On 19 September 2025 the FDA approved Forzinity (elamipretide) injection, a prescription medicine from Stealth BioTherapeutics, 'to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg'. It is an accelerated approval, and continued approval may depend on a confirmatory trial. SS-31 sold online is not this product and is an unapproved drug.
The full history, with dates
TIMELINE. The company applied on 29 January 2024 (new drug application 215244). On 10 October 2024 an FDA advisory committee voted 10 to 6, with no abstentions, that elamipretide was effective for Barth syndrome; members on both sides said the evidence was uncertain. On 15 May 2025 the FDA declined to approve it (a 'complete response letter'). The letter said effectiveness had not been established for a standard approval, because the only placebo-controlled study showed no benefit on walking distance (p = 0.97) or fatigue (p = 0.89), and it also cited manufacturing inspection problems at the plant making the product. In the same letter the FDA said it was considering knee muscle strength as a possible basis for accelerated approval. The company resubmitted on 15 August 2025 and the FDA granted accelerated approval on 19 September 2025. APPROVED USE. The label says: improving muscle strength in adults and children with Barth syndrome weighing at least 30 kg; approved under accelerated approval based on knee extensor muscle strength, which the FDA calls an intermediate clinical endpoint; continued approval may be contingent on verifying clinical benefit in a confirmatory trial. The label also states that the drug was not superior to placebo on the trial's primary endpoints. CONFIRMATORY TRIAL. The approval letter requires a randomised, double-blind, placebo-controlled trial in Barth syndrome patients aged 5 and older, with study completion scheduled for September 2029 and the final report for March 2030, and says the FDA may withdraw the approval if the trial fails to confirm benefit or is not carried out with due diligence. A trial matching this description is registered as NCT07531251 (4TAZPower): 48 participants, 72 weeks, started 2 July 2026, recruiting in Australia, Canada and the United Kingdom when we checked (the registry lists its one US site as terminated; record last updated 9 November 2026). CHANGES TO NOVEMBER 2026. FDA's Drugs@FDA database showed only the original approval and no later supplements on 18 November 2026. DailyMed's current copy of the label was published in November 2026 and its text still carries the September 2025 revision date. We found no withdrawal, no wider approval and no approval by another country's regulator. The European Medicines Agency granted elamipretide orphan designation for Barth syndrome on 20 May 2021 (EU/3/21/2430); its page states that orphan designation does not mean the medicine is available or authorised for use. COMPOUNDING. Elamipretide does not appear on the FDA's list of substances nominated for pharmacy compounding (updated 14 May 2026) or on the FDA page of compounding substances that may present significant safety risks (current as of 22 April 2026). We found no FDA compounding advisory committee briefing document for it. A draft federal policy on compounding certain peptides, published by the Department of Health and Human Services on 30 October 2026, does not name its peptides in the notice itself; Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of 15 November 2026) names exactly six, BPC-157, epitalon, KPV, MOTS-c, semax and TB-500, and SS-31 (elamipretide) is not among them. In a warning letter dated 8 December 2025 to an ingredient supplier (Darmerica), the FDA listed 'Elamipretide (SS-31) Acetate' among ingredients sold to compounding pharmacies for drugs that would not qualify for the legal exemption for compounding, and said the product had been registered with the FDA under a different ingredient name. That inspection took place in March 2025, before Forzinity was approved, and the ingredient was the acetate salt; the approved product is the hydrochloride salt. We found no FDA statement on whether the approval changes what compounders may do. ONLINE SALES. On 24 August 2026 the FDA sent warning letters to several online sellers, including Royal Peptides and Peak Performance Peptides, naming SS-31 among products it called unapproved new drugs despite 'research use only' labelling.
Source: dailymed.nlm.nih.gov (source dated 2026-11-11)
In sport: Not named on the WADA Prohibited List for 2026 (in force from 1 January 2026) or 2027 (in force from 1 January 2027); neither List mentions elamipretide or SS-31, and no other section names it. Class S0 (Non-approved substances) covers only 'any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use'. Elamipretide has had an FDA approval (as Forzinity) since 19 September 2025, so S0 does not catch it merely because it is unnamed. Read plainly, S0 depends on whether the substance has any approval, not on what a person uses it for or where it was bought. WADA has not published a ruling on elamipretide that we could find; anyone subject to anti-doping rules should ask their anti-doping organisation. WADA
Claims and what the evidence supports
| What people say | What the evidence supports |
|---|---|
| SS-31 is an anti-ageing peptide that reverses ageing in mitochondria. | The support comes from mice. In old mice, 8 weeks of SS-31 improved muscle energy production and treadmill endurance. In people, the only placebo-controlled test in healthy older adults gave one dose to 39 people: a borderline rise in one muscle's energy capacity was gone by day 7 and fatigue resistance did not change. No human trial has measured ageing, healthspan or lifespan. Source: pubmed.ncbi.nlm.nih.gov |
| It boosts endurance and athletic performance. | No trial has tested it in athletes or in healthy young adults; none of the 22 elamipretide studies on ClinicalTrials.gov enrolled them. In 218 patients with mitochondrial muscle disease, 24 weeks of treatment did not improve six-minute walk distance or fatigue compared with placebo. Source: pubmed.ncbi.nlm.nih.gov |
| It improves general 'mitochondrial health' and energy in healthy people. | Not studied beyond a single dose. A small study in healthy adults aged 65 to 80 (30 people planned, 4 weeks, one group with no placebo, main aim safety), led by a University of Washington investigator, was submitted to the registry in October 2025 and first posted in December 2025. Its estimated primary completion date (March 2026) has passed, the record still says recruiting and has not been updated since December 2025, and no results are posted. Source: clinicaltrials.gov |
| It is FDA-approved, so it has been proven to work. | It is approved for one rare disease through the accelerated pathway. The label itself says the drug was not superior to placebo on the trial's primary endpoints. The approval rests on knee-strength gains in 8 to 10 patients without a comparison group, and the FDA has required a placebo-controlled trial to confirm benefit, due to finish in 2029. An FDA advisory committee split 10 to 6. Source: dailymed.nlm.nih.gov |
| SS-31 sold online is the same thing as the approved medicine. | No evidence supports this. The approved medicine is a prescription product made by one company under FDA oversight. The FDA has told online sellers that their SS-31 is an unapproved new drug, and in one case found a supplier had registered an SS-31 ingredient under a different ingredient name. Source: fda.gov |
| It protects or repairs the heart. | In dogs with heart failure, three months of treatment improved heart pumping. In people it has not held up: a 71-person heart failure trial found no improvement in heart size or pumping after 28 days, and a heart attack trial found no reduction in heart muscle damage. Two other heart failure trials finished in 2017 and have no posted results. Source: pubmed.ncbi.nlm.nih.gov |
| It restores eyesight in macular degeneration. | The 176-person phase 2 trial did not meet either main goal (low-light vision or growth of the damaged area). A scan measure of light-sensing cells looked better on the drug, and that measure is now being tested in a phase 3 trial of 313 people, with results expected in 2027. Source: pubmed.ncbi.nlm.nih.gov |
| It has no real side effects. | Injection-site reactions affected every patient on the drug in the Barth syndrome trial and most patients in the larger trials. The label warns of serious allergic reactions and notes that cancer studies in animals had not been done at the time of approval. Source: dailymed.nlm.nih.gov |
What a genuine lab report should show
- Identity by mass spectrometry: the measured mass should match elamipretide's expected mass (average molecular weight about 639.8 g/mol; monoisotopic mass about 639.39 Da for the free peptide, per PubChem). A report that shows only a purity figure, with no mass result, does not prove what the substance is.
- Salt form should be stated. The approved medicine uses the hydrochloride salt (listed at 749.2 on the FDA label); an FDA warning letter described an acetate salt being sold as a raw ingredient. The salt changes how much of the weighed powder is actually peptide, so a report should say which salt was tested.
- Purity by HPLC (a method that separates a sample into its parts): the report should show the actual chromatogram trace, not just a percentage, with the method and the date of the test.
- Specific to this compound: the sequence contains a mirror-image amino acid (D-arginine) and a modified tyrosine (2,6-dimethyltyrosine). A basic mass test cannot tell a mirror-image amino acid from the ordinary form, and the 2004 founding paper found that versions without the modified tyrosine did not work in the laboratory. A thorough report would confirm the sequence, for example by fragment analysis (MS/MS), and not only the total mass.
- Amount per vial (peptide content), tested separately from purity.
- Traceability: a genuine report names the independent laboratory, carries a lot or batch number that matches the label, is dated, and can be confirmed with the laboratory directly.
- A lab report shows what is in one tested sample. It does not make a product an approved medicine, and it says nothing about safety in people.
What is not known
- Whether elamipretide truly benefits people with Barth syndrome. The placebo-controlled part of the trial was negative, and the required confirmatory trial (NCT07531251) is not due to finish until 2029.
- Compounding. We found no FDA statement on whether Forzinity's approval changes whether pharmacies may compound elamipretide. The one FDA statement we found (December 2025, about the acetate salt, based on a March 2025 inspection) treated it as not eligible.
- The death counts in the heart attack trial's registry record (10 of 150 on the drug, 3 of 147 on placebo) do not match the same record's participant-flow section (3 and 1) and are not discussed in the paper's abstract. Someone with access to the full paper should check how deaths were counted and over what period.
- Results of the NuPower phase 3 trial (102 people with mitochondrial disease from nuclear DNA faults, finished in 2024) were not posted on the registry and we did not find them in a journal. Company statements suggest results have been presented at meetings; we did not open a primary source for them.
- Two heart failure trials completed in 2017 (46 and 308 people) have no posted or published results that we could find.
- We could not find a registry record for the second phase 3 eye trial, ReGAIN, named in the ReCLAIM-2 paper.
- Long-term safety. The longest follow-up is 8 people for 168 weeks. Animal cancer studies were still required at approval.
- Whether the cardiolipin explanation holds in people. The FDA said no treatment effect on the cardiolipin blood marker had been shown.
- What is actually in products sold online as SS-31. We found no published testing of them.
- Results of the small University of Washington study in older adults (NCT07275424) are not available.
- The ReCLAIM-2 paper gives two different sets of figures for how many people stopped because of side effects.
Sources
All 44 sources
- Forzinity (elamipretide) label on DailyMed, current version published November 2026. dailymed.nlm.nih.gov
- FDA press announcement: FDA Grants Accelerated Approval to First Treatment for Barth Syndrome, 19 September 2025. fda.gov
- FDA accelerated approval letter, NDA 215244 (indication, confirmatory trial requirement and timetable). accessdata.fda.gov
- FDA Drug Trials Snapshot: Forzinity (content current as of 13 May 2026). fda.gov
- Drugs@FDA record for NDA 215244 (approval history; no supplements listed on 18 November 2026). accessdata.fda.gov
- FDA complete response letter for NDA 215244, 15 May 2025 (openFDA complete response letters database). api.fda.gov
- FDA advisory committee final summary minutes, 10 October 2024 (vote 10 to 6). fda.gov
- TAZPOWER trial in Barth syndrome, Genet Med 2021 (PubMed). pubmed.ncbi.nlm.nih.gov
- TAZPOWER 168-week open-label extension, Genet Med 2024 (PubMed). pubmed.ncbi.nlm.nih.gov
- Natural history comparison in Barth syndrome, Orphanet J Rare Dis 2022 (PubMed). pubmed.ncbi.nlm.nih.gov
- Confirmatory trial 4TAZPower, registry record (NCT07531251). clinicaltrials.gov
- MMPOWER-3 trial in primary mitochondrial myopathy, Neurology 2023 (PubMed). pubmed.ncbi.nlm.nih.gov
- MMPOWER-3 registry record and posted results (NCT03323749). clinicaltrials.gov
- MMPOWER-3 genotype sub-group analysis, Orphanet J Rare Dis 2024 (PubMed). pubmed.ncbi.nlm.nih.gov
- NuPower phase 3 trial, registry record (NCT05162768). clinicaltrials.gov
- PROGRESS-HF heart failure trial, J Card Fail 2020 (PubMed). pubmed.ncbi.nlm.nih.gov
- Phase 1 heart failure infusion study, Circ Heart Fail 2017 (PubMed). pubmed.ncbi.nlm.nih.gov
- Heart failure with preserved ejection fraction trial, registry record, no results posted (NCT02814097). clinicaltrials.gov
- Hospitalised heart failure trial, registry record, no results posted (NCT02914665). clinicaltrials.gov
- Dog heart failure study, Circ Heart Fail 2016 (PubMed). pubmed.ncbi.nlm.nih.gov
- EMBRACE STEMI heart attack trial, Eur Heart J 2016 (PubMed). pubmed.ncbi.nlm.nih.gov
- EMBRACE STEMI registry record and posted results (NCT01572909). clinicaltrials.gov
- ReCLAIM-2 dry macular degeneration trial, Ophthalmol Sci 2025 (PubMed). pubmed.ncbi.nlm.nih.gov
- ReNEW phase 3 dry macular degeneration trial, registry record (NCT06373731). clinicaltrials.gov
- Single-dose trial in older adults, PLoS One 2021 (PubMed). pubmed.ncbi.nlm.nih.gov
- SHAPE study in older adults, registry record (NCT07275424). clinicaltrials.gov
- All elamipretide studies on ClinicalTrials.gov (22 records on 18 November 2026). clinicaltrials.gov
- Aged mice exercise study, Free Radic Biol Med 2019 (PubMed). pubmed.ncbi.nlm.nih.gov
- Aged mice brain bleed study (negative), GeroScience 2025 (PubMed). pubmed.ncbi.nlm.nih.gov
- SS-31 and cardiolipin, J Am Soc Nephrol 2013 (PubMed). pubmed.ncbi.nlm.nih.gov
- Founding paper on the peptide family, J Biol Chem 2004 (PubMed). pubmed.ncbi.nlm.nih.gov
- Review by Szeto naming the Szeto-Schiller peptides, Br J Pharmacol 2014 (PubMed). pubmed.ncbi.nlm.nih.gov
- Review by Szeto and Schiller, from discovery to clinical development, Pharm Res 2011 (PubMed). pubmed.ncbi.nlm.nih.gov
- FDA warning letter to Royal Peptides LLC, 24 August 2026 (names SS-31). fda.gov
- FDA warning letter to Peak Performance Peptides, 24 August 2026 (names SS-31). fda.gov
- FDA warning letter to Darmerica, LLC, 8 December 2025 (elamipretide acetate sold to compounders). fda.gov
- FDA list of bulk drug substances nominated for compounding under section 503A (updated 14 May 2026). fda.gov
- FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (current as of 22 April 2026). fda.gov
- HHS draft enforcement discretion policy on compounding certain peptides, Federal Register, 30 October 2026. govinfo.gov
- PubChem compound record for elamipretide, CID 11764719. pubchem.ncbi.nlm.nih.gov
- WADA 2026 Prohibited List (in force 1 January 2026). wada-ama.org
- WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov
- European Medicines Agency: orphan designation EU/3/21/2430, elamipretide for Barth syndrome (20 May 2021; not an authorisation). ema.europa.eu
Sources last checked 2026-11-18.
This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.